APOLLO HOSPITALS ENTER. L vs CORONA REMEDIES LIMITED
A side-by-side comparison of APOLLO HOSPITALS ENTER. L (APOLLOHOSP) and CORONA REMEDIES LIMITED (CORONA) — valuation, profitability, growth, and financial health — to help you judge which is the stronger buy today.
APOLLO HOSPITALS ENTER. L vs CORONA REMEDIES LIMITED are evenly matched on the numbers (7–7). The breakdown below shows where each one wins.
- Valuation31
- Profitability04
- Growth11
- Size & financial health31
Each axis shows this group's split of that metric, scaled so the leader sits at the edge. Relative to each other, not an absolute score.
Valuation
APOLLOHOSP takes 3/4How expensive each stock is relative to its earnings and book value. Lower usually means cheaper.
Profitability
CORONA takes 4/4How efficiently each company turns capital and sales into profit. Higher is better.
Growth
EvenThree-year compounded growth. Faster-growing businesses can justify a higher valuation.
Size & financial health
APOLLOHOSP takes 3/4Scale and balance-sheet strength. Bigger revenue/profit and lower debt are generally safer.
- + ["Company has delivered good profit growth of 76.2% CAGR over last 5 years", "Company has been maintaining a healthy dividend payout of 17.7%"]
- − ["Stock is trading at 13.4 times its book value", "Company might be capitalizing the interest cost"]
- + ["Company has delivered good profit growth of 23.3% CAGR over last 5 years", "Company has a good return on equity (ROE) track record: 3 Years ROE 26.5%", "Company has been maintaining a healthy dividend payout of 29.4%"]
- − ["Stock is trading at 17.0 times its book value", "Company might be capitalizing the interest cost"]
This comparison is for informational purposes only and is not investment advice. Please consult a SEBI-registered advisor before investing.